{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:42:30Z","timestamp":1777635750154,"version":"3.51.4"},"reference-count":69,"publisher":"Elsevier","isbn-type":[{"value":"9780323900188","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.mcb.2022.04.005","type":"book-chapter","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T07:10:12Z","timestamp":1658819412000},"page":"81-109","source":"Crossref","is-referenced-by-count":2,"title":["Immunoblotting-assisted assessment of JAK\/STAT and PI3K\/Akt\/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.mcb.2022.04.005_bb0010","doi-asserted-by":"crossref","first-page":"8844","DOI":"10.1128\/MCB.25.20.8844-8853.2005","article-title":"Retrotranslocation of the chaperone calreticulin from the endoplasmic reticulum lumen to the cytosol","volume":"25","author":"Afshar","year":"2005","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0015","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0020","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood-2015-09-671172","article-title":"Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms","volume":"127","author":"Araki","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0025","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0030","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1182\/bloodadvances.2020003291","article-title":"Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs","volume":"5","author":"Balliu","year":"2021","journal-title":"Blood Advances"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0035","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: Revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0040","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/jcmm.12162","article-title":"Co-targeting the PI3K\/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms","volume":"17","author":"Bartalucci","year":"2013","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0045","doi-asserted-by":"crossref","first-page":"96710","DOI":"10.18632\/oncotarget.18073","article-title":"Inhibitors of the PI3K\/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A\/CIP2A axis","volume":"8","author":"Bartalucci","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0050","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054826","article-title":"mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms","volume":"8","author":"Bogani","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0060","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1038\/s41375-021-01391-2","article-title":"Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy","volume":"35","author":"Brkic","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: A literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer Journal"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0070","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028350","article-title":"Constitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder","volume":"6","author":"Chung","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0080","first-page":"381","article-title":"Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: A case-control study","volume":"135","author":"De Stefano","year":"2020","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0085","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood.2019001103","article-title":"Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms","volume":"135","author":"Di Buduo","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0095","series-title":"An open-label, multicenter, 2-arm, dose-finding, phase 1b study of the combination of ruxolitinib and buparlisib (BKM120) in patients with myelofibrosis: Results from HARMONY study","author":"Durrant","year":"2015"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41422-020-0383-9","article-title":"Calreticulin and cancer","volume":"31","author":"Fucikova","year":"2021","journal-title":"Cell Research"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052844","article-title":"Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant","volume":"8","author":"Funakoshi-Tago","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01116-z","article-title":"Molecular pathogenesis of the myeloproliferative neoplasms","volume":"14","author":"Greenfield","year":"2021","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0115","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2141.2009.07870.x","article-title":"Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms","volume":"147","author":"Grimwade","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0120","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2011-01-330563","article-title":"Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1\/2 study in patients with myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022148","article-title":"JAK2 V617F-dependent upregulation of PU. 1 expression in the peripheral blood of myeloproliferative neoplasm patients","volume":"6","author":"Irino","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0130","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0135","doi-asserted-by":"crossref","first-page":"1792037","DOI":"10.1080\/2162402X.2020.1792037","article-title":"Surface-exposed and soluble calreticulin: Conflicting biomarkers for cancer prognosis","volume":"9","author":"Kepp","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0140","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/leu.2013.167","article-title":"AKT is a therapeutic target in myeloproliferative neoplasms","volume":"27","author":"Khan","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0145","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0150","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0155","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0160","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2009-12-259747","article-title":"JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0165","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation","volume":"102","author":"Lu","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0170","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1074\/jbc.M707125200","article-title":"Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F","volume":"283","author":"Lu","year":"2008","journal-title":"Journal of Biological Chemistry"},{"issue":"9","key":"10.1016\/bs.mcb.2022.04.005_bb0175","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1074\/jbc.M707125200","article-title":"Functional roles of calreticulin in cancer biology","volume":"283","author":"Lu","year":"2008","journal-title":"Journal of Biological Chemistry"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0180","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.bbamcr.2010.04.005","article-title":"The emerging role of the phosphatidylinositol 3-kinase\/Akt\/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis","volume":"1803","author":"Martelli","year":"2010","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular Cell Research"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0185","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2009-12-257063","article-title":"Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice","volume":"116","author":"Marty","year":"2010","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0190","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","volume":"127","author":"Marty","year":"2016","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0195","first-page":"299","article-title":"The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis","volume":"17","author":"Masarova","year":"2019","journal-title":"Clinical Advances in Hematology & Oncology"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0200","series-title":"PI3K\u03b4 inhibitor idelalisib inhibits AKT signaling in myelofibrosis patients on chronic JAK inhibitor therapy","author":"Meadows","year":"2013"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0205","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1042\/BJ20081847","article-title":"Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum","volume":"417","author":"Michalak","year":"2009","journal-title":"Biochemical Journal"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0210","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/leu.2008.275","article-title":"Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage","volume":"23","author":"Monte-M\u00f3r","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0215","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0220","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0225","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF01630378","article-title":"The minute chromosome (Phl) in chronic granulocytic leukemia","volume":"8","author":"Nowell","year":"1962","journal-title":"Blut"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0230","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL 515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Medicine"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0240","first-page":"e123","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0245","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-11-24","article-title":"Bim and Mcl-1 exert key roles in regulating JAK2 V617F cell survival","volume":"11","author":"Rubert","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0255","doi-asserted-by":"crossref","first-page":"10558","DOI":"10.1038\/s41598-019-46843-z","article-title":"Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants","volume":"9","author":"Salati","year":"2019","journal-title":"Scientific Reports"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0260","first-page":"3956","article-title":"The thrombopoietin receptor, MPL, is critical for development of a JAK2 V617F-induced myeloproliferative neoplasm","volume":"124","author":"Sangkhae","year":"2014","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0265","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ajh.22063","article-title":"The JAK2 exon 12 mutations: A comprehensive review","volume":"86","author":"Scott","year":"2011","journal-title":"American Journal of Hematology"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0270","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0275","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/leu.2016.308","article-title":"Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib","volume":"31","author":"Shide","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/bs.mcb.2022.04.005_bb0280","first-page":"106","article-title":"Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms","volume":"136","author":"Shide","year":"2020","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0285","first-page":"3388","article-title":"Molecular insights into regulation of JAK2 in myeloproliferative neoplasms","volume":"125","author":"Silvennoinen","year":"2015","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0290","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.humpath.2008.02.004","article-title":"The saga of JAK2 mutations and translocations in hematologic disorders: Pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms","volume":"39","author":"Smith","year":"2008","journal-title":"Human Pathology"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0295","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1056\/NEJMra1406186","article-title":"Myeloproliferative neoplasms","volume":"376","author":"Spivak","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0300","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1158\/2159-8290.CD-16-0238","article-title":"Molecular mechanism of mutant CALR\u2013mediated transformation","volume":"6","author":"Stanley","year":"2016","journal-title":"Cancer Discovery"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0305","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0310","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0315","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0320","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"British Journal of Haematology"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0325","first-page":"171","article-title":"Advances in understanding and management of myeloproliferative neoplasms","volume":"59","author":"Vannucchi","year":"2009","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0330","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1365-2141.2012.09246.x","article-title":"Increased phospho-mTOR expression in megakaryocytic cells derived from CD34+ progenitors of essential thrombocythaemia and myelofibrosis patients","volume":"159","author":"Vicari","year":"2012","journal-title":"British Journal of Haematology"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0335","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0340","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera","volume":"13","author":"Wernig","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0345","first-page":"1820","article-title":"ID1 promotes expansion and survival of primary erythroid cells and is a target of JAK2V617F-STAT5 signaling","volume":"114","author":"Wood","year":"2009","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/bs.mcb.2022.04.005_bb0350","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000018","article-title":"Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F","volume":"1","author":"Zaleskas","year":"2006","journal-title":"PLoS One"}],"container-title":["Methods in Cell Biology","Methods in Stem Cell Biology - Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X22000528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091679X22000528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T13:36:13Z","timestamp":1753796173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091679X22000528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323900188"],"references-count":69,"URL":"https:\/\/doi.org\/10.1016\/bs.mcb.2022.04.005","relation":{},"ISSN":["0091-679X"],"issn-type":[{"value":"0091-679X","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}